Literature DB >> 8760788

Both CD4+ and CD8+ T cells are essential to induce experimental autoimmune myasthenia gravis.

G X Zhang1, B G Xiao, M Bakhiet, P van der Meide, H Wigzell, H Link, T Olsson.   

Abstract

CD4+ T cells have been shown to be crucial in the development of experimental autoimmune myasthenia gravis (EAMG). The role of CD8+ T cells in EAMG is less well established. We previously showed that antibody depletion of CD8+ T cells in rats effectively suppresses EAMG. To further study the role and relationship of CD4+ versus CD8+ T cells in induction of EAMG, CD4-/-, CD8-/-, and CD4-8- mutant C57BL/6 mice and the parent CD4+8- wild-type mice were immunized with Torpedo acetylcholine receptor (AChR) plus complete Freund's adjuvant. Clinical EAMG was nearly completely prevented in CD4-8-, CD4-/-, and CD8-/- mice. This was associated with strongly reduced AChR-specific T and B cell responses, and with reduced levels of AChR-reactive interferon gamma (IFN-gamma) and interleukin 4 (IL-4) mRNA-expressing cells in lymphoid organs when compared with CD4+8+ wild-type mice. We conclude that (a) both CD4+ and CD8+ T cells are essential for development of EAMG, and a collaboration between these cell types may be necessary; (b) CD4+ as well as CD8+ T cells secrete IFN-gamma and IL-4, and both cytokines are involved in the development of EAMG; and (c), besides T cells, other immune cells might also be responsible for help of anti-AChR antibody production.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8760788      PMCID: PMC2192725          DOI: 10.1084/jem.184.2.349

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  44 in total

1.  CD4+ suppressor cells inhibit the function of effector cells of experimental autoimmune encephalomyelitis through a mechanism involving transforming growth factor-beta.

Authors:  W J Karpus; R H Swanborg
Journal:  J Immunol       Date:  1991-02-15       Impact factor: 5.422

2.  The purification and characterization of rat gamma interferon by use of two monoclonal antibodies.

Authors:  P H van der Meide; M Dubbeld; K Vijverberg; T Kos; H Schellekens
Journal:  J Gen Virol       Date:  1986-06       Impact factor: 3.891

3.  Cloning, expression, and purification of rat IFN-gamma.

Authors:  R Dijkema; P H van der Meide; M Dubbeld; M Caspers; J Wubben; H Schellekens
Journal:  Methods Enzymol       Date:  1986       Impact factor: 1.600

4.  CD8+ T cell homing to the pancreas in the nonobese diabetic mouse is CD4+ T cell-dependent.

Authors:  C Thivolet; A Bendelac; P Bedossa; J F Bach; C Carnaud
Journal:  J Immunol       Date:  1991-01-01       Impact factor: 5.422

5.  CD8 is needed for development of cytotoxic T cells but not helper T cells.

Authors:  W P Fung-Leung; M W Schilham; A Rahemtulla; T M Kündig; M Vollenweider; J Potter; W van Ewijk; T W Mak
Journal:  Cell       Date:  1991-05-03       Impact factor: 41.582

6.  Pathogenic mechanisms in murine autoimmune thyroiditis: short- and long-term effects of in vivo depletion of CD4+ and CD8+ cells.

Authors:  Y M Kong; H Waldmann; S Cobbold; A A Giraldo; B E Fuller; L L Simon
Journal:  Clin Exp Immunol       Date:  1989-09       Impact factor: 4.330

7.  Role of the macrophage in the pathogenesis of experimental autoimmune myasthenia gravis.

Authors:  I Kinoshita; T Nakamura; A Satoh; H Matsuo; M Seto; I Tomita; M Tsujihata; S Nagataki
Journal:  J Neurol Sci       Date:  1988-10       Impact factor: 3.181

8.  Immunotherapy for myasthenia gravis: a murine model.

Authors:  P Christadoss; M J Dauphinee
Journal:  J Immunol       Date:  1986-04-01       Impact factor: 5.422

9.  Human T-helper lymphocytes in myasthenia gravis recognize the nicotinic receptor alpha subunit.

Authors:  R Hohlfeld; K V Toyka; S J Tzartos; W Carson; B M Conti-Tronconi
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

10.  Specificity of the T cell immune response to acetylcholine receptor in experimental autoimmune myasthenia gravis. Response to subunits and synthetic peptides.

Authors:  Y Fujii; J Lindstrom
Journal:  J Immunol       Date:  1988-03-15       Impact factor: 5.422

View more
  12 in total

1.  Modulation of immune responses and suppression of experimental autoimmune myasthenia gravis by surgical denervation of the spleen.

Authors:  M Bakhiet; L-Y Yu; V Ozenci; A Khan; F-D Shi
Journal:  Clin Exp Immunol       Date:  2006-05       Impact factor: 4.330

2.  HLA class-I-restricted and colon-specific cytotoxic T cells from lamina propria lymphocytes of patients with ulcerative colitis.

Authors:  T Sunagawa; Y Yonamine; F Kinjo; M Watanabe; T Hibi; A Saito
Journal:  J Clin Immunol       Date:  2001-11       Impact factor: 8.317

Review 3.  Myasthenia gravis as a prototype autoimmune receptor disease.

Authors:  A C Hoedemaekers; P J van Breda Vriesman; M H De Baets
Journal:  Immunol Res       Date:  1997       Impact factor: 2.829

4.  Influence of CD4 or CD8 deficiency on collagen-induced arthritis.

Authors:  M Ehinger; M Vestberg; A C Johansson ; M Johannesson; A Svensson ; R Holmdahl
Journal:  Immunology       Date:  2001-07       Impact factor: 7.397

5.  The Beneficial Clinical Effects of Teriflunomide in Experimental Autoimmune Myasthenia Gravis and the Investigation of the Possible Immunological Mechanisms.

Authors:  Emel Koseoglu; Neslihan Sungur; Sabahattin Muhtaroglu; Gokmen Zararsiz; Ahmet Eken
Journal:  Cell Mol Neurobiol       Date:  2022-10-11       Impact factor: 4.231

6.  The role of CD8+CD28 regulatory cells in suppressing myasthenia gravis-associated responses by a dual altered peptide ligand.

Authors:  Hava Ben-David; Amir Sharabi; Molly Dayan; Michael Sela; Edna Mozes
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-23       Impact factor: 11.205

7.  A dual altered peptide ligand down-regulates myasthenogenic T cell responses by up-regulating CD25- and CTLA-4-expressing CD4+ T cells.

Authors:  Miri Paas-Rozner; Michael Sela; Edna Mozes
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-12       Impact factor: 11.205

8.  CD4+ T cells, but not CD8+ T cells, are required for the development of experimental autoimmune gastritis.

Authors:  H D De Silva; I R Van Driel; N La Gruta; B H Toh; P A Gleeson
Journal:  Immunology       Date:  1998-03       Impact factor: 7.397

9.  Standardization of the experimental autoimmune myasthenia gravis (EAMG) model by immunization of rats with Torpedo californica acetylcholine receptors--Recommendations for methods and experimental designs.

Authors:  Mario Losen; Pilar Martinez-Martinez; Peter C Molenaar; Konstantinos Lazaridis; Socrates Tzartos; Talma Brenner; Rui-Sheng Duan; Jie Luo; Jon Lindstrom; Linda Kusner
Journal:  Exp Neurol       Date:  2015-03-18       Impact factor: 5.330

10.  cFLIP overexpression in T cells in thymoma-associated myasthenia gravis.

Authors:  Djeda Belharazem; Berthold Schalke; Ralf Gold; Wilfred Nix; Mario Vitacolonna; Peter Hohenberger; Eric Roessner; Torsten J Schulze; Güher Saruhan-Direskeneli; Vuslat Yilmaz; German Ott; Philipp Ströbel; Alexander Marx
Journal:  Ann Clin Transl Neurol       Date:  2015-07-22       Impact factor: 4.511

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.